

# Open Source Tools to De-risk AD Target Predictions


Lara Mangravite PhD







Division of Wharton Company P.O. BOX 1000  
**INTERNATIONAL AMUSEMENT SYSTEMS**



**Identification of target predictions  
catalyzed by systems biology**

**Evaluation of target predictions  
catalyzed by open science**

In the absence of prior knowledge, how do you distinguish poor target predictions from dark target predictions?

In the absence of prior knowledge, how do you distinguish poor target predictions from dark target predictions?

*Open Science*



# Open data to increase confidence in predictions



**60,000 files** shared by **42 investigators** across **22 institutions** representing samples from **36 research studies**

3 rat models

15 genomic data modalities

17 mouse models

10 drosophila models

7043 human samples

22 model system studies

13 human cell models

14 diagnoses

15 human studies




RADC Research Resource Sharing Hub







# Identify generalizable observations from across the consortium




RNAseq Working Group




Network Working Group



eQTL Working Group



Deconvolution Working Group



139 mouse model Differentially Expressed Genes (DEGs) in Brain

Cross-Species Working Group

# Accumulate evidence for target predictions from across AMP-AD

geneSym Region	Layer1	Layer2	Layer3	Layer4	Layer5	Layer6	RankScore_k_in_top	pubmedCpubmedC	Worm.ort	Fly.orthol	Mouse.ort	mean_Ast	mean_Enr	mean_Mi	mean_Ne	mean_Oli	mean_IPS	mean_HM	mean_IPS	mean_pA	mean_IPS	is.immune
PLXNB3 BM2	7	38	100	217	374	515	0.480795	85	0		plv-1.pkv-FBgn0025.Plxnb3	1.842249	1.101031	0	0.205299	0.62108	0.90444	1.785239	54.56941	30.88028	19.15856	NA
ATP11A BM6	8	50	131	240	363	478	0.806245	9	0		wha-13	168.6346	138.8499	442.2363	831.0098	208.1563	366.6274	369.0135	64.95947	63.53446	65.58719	NA
PREP1 BM6	7	45	141	254	388	465	0.824514	7	1	23485813	FBgn0032.Prep1	98.13387	85.54561	150.9547	580.8568	278.4382	30.46931	23.08672	78.71727	54.92785	76.61288	NA
GABRB2 BM6	19	79	162	269	357	450	0.84909	5	1	20888417	gab-1	31.26505	28.65736	0.239217	642.1141	25.99352	1.486837	2.565852	0.638538	1.77879	0.687589	NA
OAT BM6	17	70	158	236	332	431	0.462744	100	2	26764435	C16A3.10	565.2447	459.8682	237.2439	546.2507	289.4883	79.205	81.07979	65.7252	58.5178	60.36607	NA
CLTC BM6	16	64	129	192	284	392	0.53951	54	0		ctc-1	415.4341	317.8552	570.6399	572.7174	421.5224	763.8088	775.5931	630.998	512.2617	247.7109	TRUE
CLSTN3 BM6	19	63	145	232	288	315	0.53401	69	3	27010282	casy-1	33.78531	0.668914	0	48.01558	1.201666	5.900816	4.799786	23.82711	32.47991	89.92883	NA
STAT3 BM6	33	103	162	211	251	273	0.61382	29	39	27306655	sta-1	134.9197	95.69395	75.26738	69.83217	81.21607	162.236	194.9765	225.313	200.9993	294.4464	TRUE
SCN2A BM2	15	60	136	190	225	252	0.996808	2	1	11955495	FBgn0064.Scn2a1	36.48817	97.77494	0.144283	964.4424	53.71501	NA	NA	20.32881	2.044302	17.32819	NA
STB3A3 BM6	14	36	61	112	188	230	0.855659	73	0		Sb3a3	1.316151	44.1992	0	161.3374	12.39321	NA	NA	0.469425	0.64032	2.93488	NA
LAPTM5 BM2	13	53	122	178	205	221	0.537875	56	0		FBgn0040.Laptm5	0.106066	0	801.343	12.77265	11.73224	2170.205	2111.734	0.57717	0.155815	0.179616	NA
TUN1 BM2	12	44	94	142	181	205	0.616022	27	0	Y716128	FBgn0260.Tun1	60.93569	89.3179	96.74341	34.10808	35.1842	1005.908	1272.093	648.9734	508.1263	210.1413	NA
PLXNB1 BM6	16	49	100	140	160	177	0.654468	19	0		plv-1.pkv-FBgn0025.Plxnb1	131.9302	19.53324	0.202008	12.00893	88.60671	0.853873	2.675884	94.09172	128.0527	208.5335	NA
SYT1 BM6	11	27	59	94	126	162	0.738111	11	4	27192734	synt-1	111.9558	188.0778	2.094353	1959.427	216.5924	1.361645	0.883989	66.91156	6.516135	43.2029	NA
SNRPB BM6	5	20	47	88	139	162	0.478157	88	0		snp-2	34.12056	28.21835	23.84988	274.006	63.49879	2.026755	1.31522	10.44817	4.625719	25.74816	NA
SYNBP5 BM6	9	49	108	140	150	152	1	1	0	tom-1	FBgn0030.Synbp5	22.15779	7.74658	0	257.2706	14.68863	0.0709	0.181089	10.75764	0.613963	4.07375	NA
IPCEF1 BM6	7	31	68	98	125	151	0.543313	51	0		cnk-1	1.319019	0.93587	313.2563	56.90519	0.133593	43.85008	5.274469	0.197529	0.200551	6.856131	NA
PTPRC BM6	21	48	79	105	117	122	0.534285	58	4	25904803	ct-1	0.126108	0	840.8779	5.857045	0.087377	556.399	542.732	0.050719	0.027689	0.121665	TRUE
PGM2L1 BM6	6	19	41	73	110	119	0.606495	32	0	Y49F48.5	FBgn0033.Pgm2l1	41.39417	62.66841	0.244454	549.8055	58.20443	69.16821	24.62011	23.1106	30.4392	48.74624	NA
OXR1 BM6	15	48	81	97	108	108	0.4944	74	0	F52L1.13	FBgn0013.Oxr1	111.158	73.84945	487.8827	895.2432	229.8183	83.59603	50.31907	37.75737	32.24421	40.78274	NA
ITPKB BM6	14	45	66	81	84	84	0.615499	28	4	27485122	Itpe-2	170.5194	15.20195	0.388404	7.746039	84.14657	131.9887	52.09112	52.38168	48.40104	199.4526	NA
BEK2 BM6	5	22	46	63	77	84	0.549253	48	0			37.38837	15.96159	1.661769	388.6237	85.76384	0.182965	0.303398	0.571604	3.559767	21.88887	NA
YAP1 BM6	12	31	51	63	69	72	0.573063	40	0	F1365.4	FBgn0034.Yap1	65.80892	16.44811	0.159675	2.715889	0	0.782943	2.78804	105.2838	115.0456	105.0383	NA
FLJ0043 BM6	14	38	56	59	68	72	0.510465	67	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
NHS1L1 BM6	8	32	55	66	70	70	0.565568	41	0			925.9085	116.2174	351.5957	15.84129	2.089532	10.34856	16.20556	81.84442	38.33485	95.15214	NA
GPR158 BM10	5	19	33	49	64	67	0.479397	87	0	F38E2.8	FBgn0051.Gpr158	2.488375	1.739343	7.664397	91.00083	2.980566	NA	NA	31.29134	2.014838	1.97662	NA
LPP10 BM6	15	37	61	66	66	66	0.740791	10	1	22734645	Lpp10	41.82685	93.50068	0.105327	0.459894	34.93363	211.7742	261.5741	201.9834	108.5608	144.574	NA
INPP5D BM6	9	34	52	64	66	66	0.653574	42	9	28054028	12299.10	2754021	2.889866	15.26649	0.108337	0.030322	141.3368	132.0936	1.733459	0.784304	8.941674	NA
WDR11 BM6	5	27	52	58	58	58	0.589341	34	0			4.209612	191.0391	0.131813	31.10212	5.938066	2.018107	281.4128	310.3445	124.3911	NA	
RP11-533L BM6	12	32	50	56	57	57	0.480068	86	NA			138.5842	77.06258	23.32954	32.66445	60.52765	0.384813	2.574166	6.838285	14.67634	12.77521	NA


High



Low

Drugability Index





**AMP-AD**



**M2OVE-AD Consortium**

*189 investigators*



**Model AD Program**



**Resilience-AD Program**

ENTER  
AIR-GAP

0  
5  
9






# Agora

[agora.ampadportal.org](http://agora.ampadportal.org)

- broadcast target predictions
- aggregate target evidence
- disseminate tools
- communicate independent evaluations

# Early sharing of target predictions from systems evaluation of human disease

[View all nominated targets](#)

Gene name 	Nominations 	Teams 
ABCA7	1	Duke
ADAM9	1	Duke
AK4	1	Broad-Rush-Columbia
ALK	1	Mayo-UFL-ISB
AP2B1	1	Emory
ATP2B1	1	MSSM

<http://agora.ampadportal.org>

# AMP-AD Evidence in Support of VGF

## MSSM

The Icahn School of Medicine at Mount Sinai team, led by Eric Schadt, Bin Zhang,

### Why was the target selected?

VGF was selected as a target because it was downregulated in AD cases. It was

### Predicted therapeutic direction

VGF activation is hypothesized to rescue diseases. In human postmortem brain improves neurogenesis in the subgranular zone of hippocampus, and partially re

### The type of data used and analyses done to identify target

Bayesian network analysis derived from RNAseq and SNP genotypes.

[link to MSSM team](#)

## Emory

The Emory team, led by Allan Levey, focuses on the generation and analysis of prote

### Why was the target selected?

VGF was identified as both a potential driver and a protein linking different groups, negatively correlated with the two hallmark pathologies of AD, namely CERAD as a

### Predicted therapeutic direction

Don't know. Possibly activate (promote neurogenesis/homing), since reduced in AD.

### The type of data used and analyses done to identify target

Discovery quantitative proteomics of FrCx WPCNA of multiple and consensus cohort

[link to Emory team](#)

## Broad-Rush-Columbia

The Broad-Rush-Columbia team, led by Philip De Jager and David E. Cohen, focuses on the generation and analysis of proteomics data from two prospective cohort studies of aging and dementia. They use data on cognitive decline in older age, as well as resilience to the brain pathologies. Fir

### Why was the target selected?

This gene was found to have large correlations with AD status in the

### Predicted therapeutic direction





Upregulate

### The type of data used and analyses done to identify target

SRM protein levels.


[link to Broad-Rush-Columbia team](#)

# AMP-AD Evidence in Support of VGF





# Open experimental tools for target evaluation



**The SGC:** A public-private partnership that supports the discovery of new medicines through open access research



Opher Gileadi  
Paul Brennan  
May Khanna



Center for Innovation in  
Brain Science



# Acknowledgements



SageBionetworks

Ben Logsdon  
Thanneer Perumal  
Solly Sieberts  
Kenny Daily  
Anna Greenwood

Larsson Omberg  
Mette Peters  
Yooree Chae  
Kara Woo  
Christine Suver

Mike Kellen  
Woody MacDuffie  
Stockard Simon  
Xa Schildwachter  
Jay Hodgson

David Collier - Lilly  
Eric Schadt and Noam Beckman – Mt Sinai  
Nathan Price and Cory Funk – ISB  
Paul Brenna and Opher Gileadi – Oxford  
May Khanna – U Arizona

All AMP-AD , M<sup>2</sup>OVE-AD, MODEL-AD, and Resilience AD Investigators  
Suzana Petanceska and the National Institute of Aging



### AMP-AD Knowledge Portal

[synapse.org/ampad](https://synapse.org/ampad)

*Access data and  
learn more about AMP-AD*



### Agora

[agora.ampadportal.org](https://agora.ampadportal.org)

*View AMP-AD targets  
and explore results*

Visit us at AAIC at Booth #103

[@AMPADPortal](https://twitter.com/AMPADPortal)